



Consolidated Financial Result Briefing for the nine months ended December 31, 2025

CYBERDYNE Inc. (Ticker Code: 7779)
February 12, 2026

Consolidated Nine months Results Summary (IFRS)

Consolidated revenue decreased due to the impact of the sale of subsidiaries in the previous fiscal year, while operating profit improved year on year

Profit before tax and profit attributable to owners of parent increased mainly due to gains on valuation of investment securities, resulting in an expansion of profitability

(Millions of yen)	FY2024 3Q	FY2025 3Q	'+/-	+/- %
Revenue	3,169	2,893	△ 276	△ 8.7%
Operating profit (loss)	△ 708	△ 274	+ 434	-
Profit (loss) before tax	△ 297	368	+ 665	-
Profit (loss) attributable to owners of parent	△ 384	190	+ 574	-

Revenue

2,893 Million
YoY -276 Million (-8.7%)

- EMEA product rentals: +146 million yen (business +138 million yen, forex +8 million yen)
- Domestic & APAC product rentals, etc.: +58 million yen (business +70 million yen, forex -12 million yen)
- Treatment services: -119 million yen (business -94 million yen, forex -25 million yen)
- Others: LeyLine -337 million yen, domestic -26 million yen

Operating profit (loss)

-274 Million
YoY +434 Million

- EMEA product rentals: +99 million yen (business +96 million yen, forex +3 million yen)
- Domestic & APAC product rentals, etc.: +104 million yen (business +112 million yen, forex -8 million yen)
- Treatment services: +24 million yen (business +23 million yen, forex +1 million yen)
- Others: LeyLine +121 million yen, domestic +44 million yen
- R&D and head office expenses, etc.: +57 million yen

Profit (loss) before tax

368 Million
YoY +665 Million

- Operating profit variance: +434 million yen
- Gain on valuation of investment securities: +188 million yen
(FY2025 3Q YTD: +512 million yen vs. FY2024 3Q YTD: +324 million yen)
- Finance costs -208 million yen (FY2025 3Q YTD: -256 million yen vs. FY2024 3Q YTD: -48 million yen)
- FY2025 : Provision for doubtful accounts for LeyLine -252 million yen
- Others (Gains related to CEJ Fund, etc.): +251 million yen

※ Exchange Rate USD/JPY: Mar 149.52 → Sep 148.88 → Dec 156.56 (YoY: Mar 151.41 → Sep 142.73 → Dec 158.18)
EUR/JPY: Mar 162.08 → Sep 174.47 → Dec 184.33 (YoY: Mar 163.24 → Sep 159.43 → Sep 164.92)

Consolidated results: Revenue / Operating profit (Margin) (Nine-month period)

Product rentals and related services recorded year-on-year increases in both revenue and profit, driven by continued expansion in EMEA, APAC, and Japan

Treatment services recorded a decrease in revenue but an increase in profit

(Millions of yen)		FY2024 3Q	FY2025 3Q	+/-	+/- %
Product rental	Revenue	1,302	1,507	+205	+ 16%
	Operating Profit (Margin %)	525 (40%)	713 (47%)	+188 (+7%)	+ 36%
Treatment service	Revenue	1,345	1,226	△ 119	△ 9%
	Operating Profit (Margin %)	△ 101 (△7%)	△ 76 (△6%)	+24 (+1%)	-
Others	Revenue	522	160	△ 362	△ 69%
	Operating Profit (Margin %)	△ 155 (△30%)	10 (6%)	+165 (+36%)	-
R&D expenses& Head office expenses	Adjusted amount	△ 978	△ 921	+57	-
Consolidated total(IFRS)	Revenue	3,169	2,893	△ 276	△ 9%
	Operating Profit (Margin %)	△ 708 (△22%)	△ 274 (△9%)	+434 (+13%)	-

Note: As a result of the sale of LeyLine GmbH at the end of February 2025, the reporting segment previously presented as “New Business Expansion” has been reclassified as “Others” due to its reduced materiality.

- Amount of operating profit or loss, which is revenue minus operating expenses, for each business
- Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Product rental : Revenue from rental of the Group's products (includes revenue from sales)
- Treatment service : Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- Others : Revenue from the Group's other business (e.g. subsidiary in Sleeping App)

Revenue by geographical regions and type of transaction (Nine-month period)

(Unit : Millions of yen) Top : 2025 3Q YTD (Bottom : 2024 3Q YTD)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	728 (684)	348 (201)	403 (388)	29 (28)	1,507 (1,302)	+205 (+ 16%)
Treatment Service	91 (96)	54 (44)	- (-)	1,081 (1,205)	1,226 (1,345)	△ 119 (△ 9%)
Others	160 (186)	- (337) *	- (-)	- (-)	160 (522)	△ 362 (△ 69%)
Total	979 (966)	402 (582)	403 (388)	1,110 (1,233)	2,893 (3,169)	△ 276 (△ 9%)
YoY	+12 (+ 1%)	△ 180 (△ 31%)	+15 (+ 4%)	△ 123 (△ 10%)		
	Domestic	Foreign				
Revenue to sales ratio	34%	66%			100%	

EMEA :Europe, the Middle East and Africa

APAC : Asia-Pacific *Excluding Japan

AMER : North, Central and South America

* Impact of the sale of LeyLine GmbH (at the end of February 2025)

Rental revenue by each products (Nine-month period)

Domestic sales remained solid, supported by new installations of the Medical HAL Lower Limb Type(including small-size HAL) and HAL Single Joint Type

Overseas sales also remained strong, supported by new installations of the Medical HAL Lower Limb Type, HAL Single Joint Type, and HAL Lumbar Type, mainly in EMEA (primarily Germany) and APAC (primarily Malaysia)

(Unit : Millions of yen) Top : 2025 3Q YTD (Bottom : 2024 3Q YTD)	Type of product	In Japan	Outside Japan	Total
Cybernics Treatment Functional improvement and regeneration	Medical HAL Lower Limb Type	320 (278)	537 (410)	858 (687)
	Non-medical HAL Lower Limb Type	111 (118)	- (-)	111 (118)
	HAL Single Joint Type	70 (65)	113 (87)	183 (151)
Well-being and care	HAL Lumbar Type	66 (78)	98 (66)	164 (145)
Labor Support	HAL Lumbar Type	28 (29)	- (-)	28 (29)
	Mobile robot (CL02 etc.)	65 (54)	- (-)	65 (54)
Other (Acoustic X, Other products)		69 (63)	30 (55)	99 (118)
Total		728 (684)	779 (618)	1,507 (1,302)

Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.



CYBERDYNE